CorMedix (CRMD) director exercises 15,000 options, holds 95,498 shares

Rhea-AI Filing Summary

CorMedix Inc. director Steven W. Lefkowitz reported exercising stock options for 15,000 shares of common stock on January 12, 2026. The options had an exercise price of $5.63 per share, and he paid the exercise price in cash. The filing states that no sales of stock were made in connection with this transaction.

After the option exercise, Lefkowitz directly beneficially owns 95,498 shares of CorMedix common stock. He also indirectly beneficially owns 30,152 shares through the Wade Capital Corporation Money Purchase Plan, an entity for which he has voting and investment control, and an additional 2,000 shares are held indirectly through his wife. The exercised option covering 15,000 shares was fully vested and now shows a remaining balance of zero.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC.,

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		M		15,000	A	$5.63	95,498(1)	D
Common Stock								30,152	I(2)	Wade Capital Corporation Money Purchase Plan
Common Stock								2,000	I	Reporting Person's Wife

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$5.63	01/12/2026		M			15,000	(3)	02/25/2030	Common Stock	15,000	$0.00	0	D

Explanation of Responses:

1. The Reporting Person acquired stock through the exercise of options granted on 02/25/2020. The Reporting Person paid the exercise price in cash. No sales of stock were made.

2. The Reporting Person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which the Reporting Person has voting and investment control).

3. These stock options, representing a right to purchase 15,000 shares of Common Stock, were granted on 02/25/2020. These stock options are fully vested.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CorMedix (CRMD) report for January 12, 2026?

Director Steven W. Lefkowitz exercised stock options for 15,000 shares of CorMedix common stock on January 12, 2026 at an exercise price of $5.63 per share, with no stock sales reported.

How many CorMedix (CRMD) shares does Steven W. Lefkowitz own after this Form 4 filing?

Following the reported transaction, Steven W. Lefkowitz directly beneficially owns 95,498 shares of CorMedix common stock, plus indirect holdings of 30,152 shares through the Wade Capital Corporation Money Purchase Plan and 2,000 shares held by his wife.

Did the CorMedix (CRMD) director sell any shares in this Form 4 transaction?

No. The footnotes state that the Reporting Person paid the exercise price in cash to acquire 15,000 shares through option exercise and that no sales of stock were made.

What happened to the CorMedix stock options reported in this Form 4?

The filing shows a stock option (right to buy common stock) for 15,000 shares at an exercise price of $5.63, granted on February 25, 2020, fully vested, and exercised on January 12, 2026, leaving 0 derivative securities beneficially owned afterward.

How are the Wade Capital Corporation Money Purchase Plan holdings in CorMedix (CRMD) characterized?

The filing explains that the Reporting Person beneficially owns 30,152 shares of CorMedix common stock through the Wade Capital Corporation Money Purchase Plan, an entity for which he has voting and investment control.

What indirect CorMedix (CRMD) holdings related to the director’s spouse are disclosed?

The Form 4 notes an indirect holding of 2,000 shares of CorMedix common stock described as held by the Reporting Person's wife.